<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01492933</url>
  </required_header>
  <id_info>
    <org_study_id>120032</org_study_id>
    <secondary_id>12-AA-0032</secondary_id>
    <nct_id>NCT01492933</nct_id>
  </id_info>
  <brief_title>Measuring Effects of Alcohol on Brain Chemistry</brief_title>
  <official_title>Measuring Effects of Acute Ethanol on Human Brain Metabolites Using Magnetic Resonance Spectroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:

      - Studies show that alcohol changes the amount of many brain chemicals. These changes may be
      related to continued drinking, craving for alcohol, and relapse. This study will use magnetic
      resonance imaging (MRI) to look at brain areas and brain chemistry during an infusion of
      alcohol. It will also study how changes in brain chemistry relate to participant reports of
      feeling drunk.

      Objectives:

      - To use magnetic resonance imaging to measure the effect of alcohol on brain chemistry

      Eligibility:

        -  Individuals between 21 and 45 years of age.

        -  Participants will be either light drinkers (1 to 14 standard alcoholic drinks per week)
           or heavy drinkers (20 to 40 standard alcoholic drinks per week). A standard drink is a
           12-ounce beer, a 4-ounce glass of wine, or a shot of liquor.

        -  Participants must be able to go without alcohol for at least 3 days in a row without
           severe withdrawal symptoms.

      Design:

        -  This study requires two or three outpatient visits to the NIH Clinical Center.

        -  Participants will have a physical exam and medical history. Blood and urine samples will
           be collected. Participants' alcohol drinking habits will also be assessed to determine
           whether they may have an alcohol use disorder.

        -  At the first study visit, participants will have an infusion of alcohol. Blood samples
           will be collected to measure blood alcohol levels.

        -  The MRI study visit will take place about 3 days after the first study visit.
           Participants will have an MRI scan of the brain, followed by an infusion of alcohol and
           another scan. Blood samples will be collected.

        -  Participants will complete questionnaires before and after each infusion to measure
           their response to alcohol.

        -  Heavy drinkers will come to the clinic for a third visit to discuss possible future
           treatment and any risky behavior associated with their high levels of alcohol use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rodent studies have indicated that modulation of glutamatergic transmission contributes to
      alcohol intoxication, reinforcement, tolerance, and dependence. Brain microdialysis studies
      have in general shown that acute alcohol suppresses glutamate release, while alcohol
      withdrawal leads to progressively increased extracellular levels.

      Here, we will use an acute, pharmacokinetically controlled alcohol challenge and magnetic
      resonance spectroscopy (MRS) to study the relationship between brain alcohol and glutamate
      concentrations, and correlate these with subjective feelings of alcohol effects, as measured
      by the Drug Effects Questionnaire (DEQ) in human subjects. Correlations between MRS data and
      other behavioral data from the Sensitivity to Punishment and Sensitivity to Reward
      Questionnaire (SPSRQ), Alcohol Sensitivity Questionnaire (ASQ), and the Alcohol Effects
      Questionnaire (AEFQ) will be investigated.

      Healthy participants aged 21-45, without gross impairment of judgment or complicated
      psychiatric or other morbidity, will receive a preliminary infusion to ensure no adverse
      effects from intravenous (IV) alcohol administration to a target BAC of 0.08g/dl. In a
      subsequent session, participants will be infused with alcohol to the same target level while
      being scanned in the MR scanner and reporting subjective feelings using the DEQ. Two groups
      of subjects will be recruited: heavy drinkers, classified as females who consume 15 plus
      drinks per week and males who consume 20 plus drinks per weekthose who consume between 20 and
      40 drinks per week, and light drinkers, classified as females who consume between 1 and 10
      drinks per week and males who consume between 1 and 14 drinks per week. those who consume
      between 1 and 14 drinks per week.

      Central glutamate levels will be quantified at 3T using pharmacologically validated MRS
      methodology recently published from our laboratory, and its relationship to central alcohol
      levels will be determined. Relationships will also be analyzed between DEQ scores and brain
      glutamate and alcohol levels. Finally, it will be examined whether drinking history (i.e.
      being a light versus heavy drinker) is a moderator of any of these relationships.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>November 22, 2011</start_date>
  <completion_date>February 24, 2015</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>What is the correlation between measured blood and breath alcohol level and ethanol level concentration computed from MRS.</measure>
    <time_frame>End of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Does ethanol administration similarly affect the metabolite activities in all the regions of the brain Gray and White matter?</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure: Does ethanol metabolite concentration correlate with any of subjective effects of ethanol as measured by response to DEQ questions?</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy Volunteers</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA (Light Drinkers)

               1. In good health as determined by medical history, physical exam, ECG and lab
                  tests;

               2. Between 21 and 45 years of age;

               3. Currently consuming between 1 and 10 drinks per week for females and 1 and 14
                  drinks per week for males.

        EXCLUSION CRITERIA (Light Drinkers)

          1. Have liver function tests (AST, ALT, GGT, ALP) 3-times the upper limit of normal
             (ULN); or have Total Bilirubin above 1.5 ULN and Albumin below 3.5 g/dL.

          2. Have fulfilled DSM-IV criteria for a current or past major psychiatric disorder
             including alcohol or other substance dependnece (excluding nicotine);

          3. Have a Body Mass Index (BMI) value over 35;

          4. Unable to stop taking any prescribed, non-prescribed, or over-the-counter medication
             or drugs 3 days prior to study days (excluding oral contraceptive agents). If a
             subject is taking a prescribed medication (excluding oral contraceptive agents) that
             is not take-as-needed they will be excluded from participation;

          5. Are pregnant, as determined by a negative pregnancy test, or lactating;

          6. Report to have a &quot;facial flushing&quot; response to the consumption of alcohol;

          7. Have never consumed at least two standard drinks of alcohol within one hour;

          8. Have ferromagnetic objects in their bodies, which might be adversely affected by MRI
             including implanted pacemakers, medication pumps, aneurysm clips, metallic prostheses
             (including metal pins and rods, heart valves or cochlear implants), shrapnel
             fragments, permanent eye liner or small metal fragments in the eye that welders and
             other metal works may have any doubt about presence of these objects will result in
             exclusion from this study);

          9. Regular tobacco users will be excluded from the study in order to avoid nicotine
             withdrawal symptoms. Occasional (not daily) use of tobacco products is acceptable;

         10. Unwilling to abstain from alcohol for at least 2 days prior to the studies.

        INCLUSION CRITERIA (Heavy Drinkers)

          1. In good health as determined by medical history, physical exam, ECG and lab tests;

          2. Between 21 and 45 years of age;

          3. Currently consuming 15+ drinks for females and 20+ drinks for males;

          4. Not regularly abstinent for more than 3 days per week, but have abstained from alcohol
             for 3 consecutive days without experiencing withdrawal symptoms;

          5. Able to provide a plausible history that they can abstain from alcohol without
             significant withdrawal symptoms when coming to the clinic. In addition, participants
             will be asked to quantify their worst withdrawal symptoms using the Clinical Institute
             Withdrawal Assessment (CIWA) Instrument. Participants who score 8 or above will not be
             enrolled in the protocol;

          6. Not seeking treatment for their alcohol consumption.

        EXCLUSION CRITERIA (Heavy Drinkers)

          1. Have liver function tests (AST, ALT, GGT, ALP) 3-times the upper limit of normal
             (ULN); or have Total Bilirubin above 1.5 ULN and Albumin below 3.5 g/dL.

          2. Have fulfilled DSM-IV criteria for a current or past major psychiatric disorder,
             including any substance dependence (excluding alcohol or nicotine) at any time;

          3. Have a Body Mass Index (BMI) value over 35;

          4. Unable to stop taking any prescribed, non-prescribed, or over-the-counter medication
             or drugs 3 days prior to study days (excluding oral contraceptive agents). If a
             subject is taking a prescribed medication (excluding oral contraceptive agents) that
             is not take-as-needed they will be excluded from participation;

          5. Are pregnant, as determined by a negative pregnancy test, or lactating;

          6. Report to have a &quot;facial flushing&quot; response to the consumption of alcohol;

          7. Have never consumed at least two standard drinks of alcohol within one hour;

          8. Have ferromagnetic objects in their bodies, which might be adversely affected by MRI
             including implanted pacemakers, medication pumps, aneurysm clips, metallic prostheses
             (including metal pins and rods, heart valves or cochlear implants), shrapnel
             fragments, permanent eye liner or small metal fragments in the eye that welders and
             other metal works may have any doubt about presence of these objects will result in
             exclusion from this study);

          9. Regular tobacco users will be excluded from the study in order to avoid nicotine
             withdrawal symptoms. Occasional (not daily) use of tobacco products is acceptable;

         10. Unwilling to abstain from alcohol for at least 2 days prior to the studies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Momenan, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Beckmann CF, Smith SM. Tensorial extensions of independent component analysis for multisubject FMRI analysis. Neuroimage. 2005 Mar;25(1):294-311. Epub 2005 Jan 8.</citation>
    <PMID>15734364</PMID>
  </reference>
  <reference>
    <citation>Romanos GE, Schr√∂ter-Kermani C, Bernimoulin JP. [Collagen as a basic element of the periodontium: immunohistochemical aspects in the human and animals. 2. Cementum and periodontal ligament]. Parodontol. 1991 Feb;2(1):47-59. German.</citation>
    <PMID>1854918</PMID>
  </reference>
  <reference>
    <citation>Behrens TE, Berg HJ, Jbabdi S, Rushworth MF, Woolrich MW. Probabilistic diffusion tractography with multiple fibre orientations: What can we gain? Neuroimage. 2007 Jan 1;34(1):144-55. Epub 2006 Oct 27.</citation>
    <PMID>17070705</PMID>
  </reference>
  <verification_date>February 24, 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2011</study_first_submitted>
  <study_first_submitted_qc>December 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2011</study_first_posted>
  <last_update_submitted>May 19, 2018</last_update_submitted>
  <last_update_submitted_qc>May 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <keyword>Ethanol</keyword>
  <keyword>Magnetic Resonance Spectroscopy</keyword>
  <keyword>Spectroscopy</keyword>
  <keyword>Alcohol Use</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

